LAMA2 and Stroke: Additionally, comparison of the expression level of LAMA2, MLL4, PLXDC2, CD14, CLU, CD99 and SAA2 in sera of healthy volunteers and patients with stroke and pre-diabetes suggests that LAMA2, MLL4 and PLXDC2 have better specificity for (pre-)diabetes than CD14, CLU, CD99 and SAA2 (Figure 4 and Supplementary Figure 3) (41).